Sparc-like protein 1 is a new marker of human glioma progression. by Turtoi, Andrei et al.
Sparc-Like Protein 1 Is a New Marker of Human Glioma Progression
Andrei Turtoi,*,†,‡ Davide Musmeci,†,§ Antonio Giuseppe Naccarato,§ Cristian Scatena,§ Valerio Ortenzi,§
Robert Kiss,∥ Daniela Murtas,⊥ Georgios Patsos,† Gabriel Mazzucchelli,‡ Edwin De Pauw,‡
Generoso Bevilacqua,§ and Vincent Castronovo†
†Metastasis Research Laboratory, GIGA-Cancer, University of Liege, Bat. B23, Liege, Belgium
‡Laboratory of Mass Spectrometry, University of Liege, Bat. B6C, Liege, Belgium
§Division of Surgical, Molecular and Ultrastructural Pathology, University Hospital of Pisa, Pisa, Italy
∥Laboratory of Toxicology, Faculty of Pharmacy, Universite ́ Libre de Bruxelles, Brussels, Belgium
⊥Department of Biomedical Sciences, Section of Cytomorphology, University of Cagliari, Cagliari, Italy
*S Supporting Information
ABSTRACT: High-grade gliomas (glioblastomas) are the
most common and deadly brain tumors in adults, currently
with no satisfactory treatment available. Apart from de novo
glioblastoma, it is currently accepted that these malignancies
mainly progress from lower grade glial tumors. However, the
molecular entities governing the progression of gliomas are
poorly understood. Extracellular and membrane proteins are
key biomolecules found at the cell-to-cell communication
interface and hence are a promising proteome subpopulation
that could help understand the development of glioma.
Accordingly, the current study aims at identifying new protein
markers of human glioma progression. For this purpose, we
used glial tumors generated orthotopically with T98G and
U373 human glioma cells in nude mice. This setup allowed
also to discriminate the protein origin, namely, human
(tumor) or mouse (host). Extracellular and membrane
proteins were selectively puriﬁed using biotinylation followed
by streptavidin aﬃnity chromatography. Isolated proteins were
digested and then identiﬁed and quantiﬁed employing 2D-
nano-HPLC−MS/MS analysis. A total of 23 and 27 up-
regulated extracellular and membrane proteins were identiﬁed
in the T98G and U373 models, respectively. Approximately
two-thirds of these were predominantly produced by the
tumor, whereas the remaining proteins appeared to be mainly
overexpressed by the host tissue. Following extensive
validation, we have focused our attention on sparc-like protein
1. This protein was further investigated using immunohis-
tochemistry in a large collection of human glioma samples of
diﬀerent grades. The results showed that sparc-like protein 1
expression correlates with glioma grade, suggesting the possible role for this protein in the progression of this malignancy.
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■ INTRODUCTION
Brain nervous tissue consists of neuronal (neurons) and non-
neuronal (glial) cells. In contrast to neurons, glial cells retain
the capability to undergo mitosis, in particular at sites of brain
damage.1,2 Astrocytes are a subpopulation of glial cells, mainly
involved in anchoring neurons to the blood supply and
controlling their chemical environment by removing excess ions
and neurotransmitters.1 This subpopulation of glial cells gives
origin to a type of brain tumor commonly known as
astrocytoma.3 Astrocytoma can develop in patients of any
age, mainly in the cerebrum, and rarely gives rise to metastasis
outside the skull. The World Health Organization (WHO)
considers diﬀerent subtypes of astrocytoma according to their
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histological degree of diﬀerentiation and their morphological
characteristics of aggressiveness.4 According to their prolifer-
ative activity, degree of atypia, and inﬁltrative behavior
astrocytomas are classiﬁed as (i) pilocytic astrocytoma or
WHO grade I (a benign and rare pediatric brain tumor), (ii)
diﬀuse astrocytomas or WHO grade II (low proliferation rate,
low grade of atypia, inﬁltration of adjacent structures), (iii)
anaplastic astrocytomas or WHO grade III (high proliferation
rate, high grade of atypia, diﬀuse inﬁltration of the nervous
tissue), and (iv) glioblastoma multiforme (GBM) or WHO
grade IV (the most aggressive type, with extreme anaplasia, very
high proliferation rate, diﬀuse inﬁltration of the nervous tissue,
prominent neo-angiogenesis, frequent areas of necrosis).4,5
GBM is the most common type of primary brain tumors in
human adults,6 with life expectancy that rarely exceeds 14
months.5 Current therapies are based on surgical resection of
the tumor followed by local radiation and adjuvant chemo-
therapy.6 The ability of GBM cells to migrate through the brain
parenchyma8 makes them an elusive target for eﬀective
treatment. Current research is focused on developing suitable
(molecular) targeted therapies that could treat GBM more
eﬀectively. Most therapies in clinical trials focus either on
blocking the epithelial growth factor receptor (EGFR) of the
tumor cells or on inhibiting angiogenesis via interfering with
vascular endothelial growth factor receptor (VEGFR) and
platelet derived growth factor receptor (PDGFR).9−12 How-
ever, because of its particular tissue features, eﬀective GBM
treatment is likely to require a more speciﬁcally tailored type of
therapy. Therefore it is of high interest to identify novel
proteins involved in the pathology of gliomas, oﬀering new
putative targets for drug discovery and more eﬃcient diagnosis.
In this respect a particular subclass of proteins, found at the
exterior of the cell (cell membrane or extracellular matrix) and
herein further referred as accessible, is particularly appealing for
identiﬁcation of novel protein targets. Such accessible proteins
bear the potential to be easily and eﬃciently reached by
systemically administered compounds (e.g., antibodies coupled
to toxic coumponds or imaging molecules). Furthermore, from
a biological point of view this subclass of proteins is located at
the interface of cell−cell and cell−extracellular matrix
Figure 1. Workﬂow of the diﬀerential proteomic analysis. The experiment commences with tumor generation and is followed by labeling of the
accessible proteins using modiﬁed biotin reagent. Biotinylated proteins are puriﬁed using streptavidin beads and digested with trypsin into peptides.
The peptides are than sequenced using 2D-nano-HPLC−MS/MS. Subsequently, the peptide sequences are compared with existing mouse and
human databases. Selected proteins are than validated using WB and IHC in mouse bearing tumors as well as relevant human samples.
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interaction, underlying the importance of their role in
fundamental cancer processes such as invasion and migration.13
Today there are no studies characterizing the membrane and
extracellular proteins in GBM. The present study is ﬁlling this
void using innovative proteomic technologies and suitable
murine in vivo models. In this work we present an extensive
proteomic analysis, oﬀering an original repertoire of modulated
accessible proteins of two astrocytic human cell lines (U373
and T98G) xenografted in mouse brain. The two cell lines have
previously been reported to display distinctive in vivo features of
anaplastic astrocytoma and glioblastoma tumors.14−18 This
model oﬀers one interesting advantage, namely, the option of
discriminating proteins produced by the tumor cells (human)
from those produced by the stroma (murine). At a pre-
analytical level, we exploit a previously developed ex vivo
biotinylation method for the selective enrichment of membrane
and extracellular proteins.19,20 This speciﬁc group of proteins is
subsequently identiﬁed and semi-quantiﬁed using mass
spectrometry.
The results highlight a repertoire of known and novel
proteins in the context of human glioma. One of these, sparc-
like protein 1 (SPRL1 [gene name: SPARCL1]), is to our
knowledge not reported to be associated with high-grade
gliomas. SPRL1 overexpression in brain tumors of xenografted
animals as well as in a large collection of human gliomas of
diﬀerent grades was conﬁrmed by validation studies employing
WB and IHC. Importantly, the expression pattern of SPRL1
correlated well with the progression stage of human glioma.
■ MATERIALS AND METHODS
Unless otherwise speciﬁed all the reagents used in the present
study were obtained from Sigma Aldrich Co. (St. Louis, MO,
USA). The in vivo experiments were performed on the basis of
authorization of the Animal Ethics Committee of the Federal
Department of Health, Nutritional Safety and the Environment
(Belgium).
Cell Culture and Animal Models
Human U373 (ATCC code HTB-17) and T98G (ATCC code
CRL1690) GBM cell lines were obtained from the American
Type Culture Collection (ATCC; Manassas, VA, USA) and
maintained as detailed previously.21 Brieﬂy, cells were cultured
at 37 °C in Falcon plastic dishes (Gibco, Nunc, Belgium)
containing Eagle minimal essential medium (MEM; Gibco,
Nunc, Belgium) supplemented with 10% fetal calf serum
(FCS), a mixture of glutamine (0.6 mg/mL ﬁnal concentration
(FC); Gibco, Nunc, Belgium), penicillin (200 IU/mL ﬁnal
concentration; Gibco, Nunc, Belgium), streptomycin (200 IU/
mL FC; Gibco, Nunc, Belgium) and 0.1 mg/mL gentamycin
(Gibco, Nunc, Belgium). The FCS was heat inactivated for 1 h
at 56 °C.
In vivo mice orthotopic xenografts were obtained by injecting
1 × 106 of either T98G or U373 cells into the left temporal
lobes of nude mice (6-week-old female nu/nu mice of 21−23 g;
Janvier, Le Genest-Saint-Isle, France) as described previously.21
A set of 9 mice were injected with each of the two cell lines,
while 9 more were injected with PBS and used as mock control.
Mice were then sacriﬁced 5 weeks after the graft, and left
hemispheres were collected. Six animals per condition were
used for biotinylation and MS analysis, whereas three of each
were kept for WB and IHC based validation.
Tissue Biotinylation and Protein Extraction
The biotinylation procedure was performed as detailed
previously (Figure 1).19 Brieﬂy, the brains were sliced and
soaked into freshly prepared EZ-link Sulfo-NHS-SS biotin (1
mg/mL, Pierce, Thermo Scientiﬁc, USA) in PBS (pH 7.4) at 37
°C for 20 min. This was followed by a 5 min quenching step
using 50 mM Tris-HCl (pH 7.4) at 37 °C. The samples were
then rinsed with PBS (PH 7.4) and snap-frozen in liquid
nitrogen. Following this, 100 mg of tissue were pulverized using
mikro-dismembrator (B. Braun Biotech, Melsungen, Germany)
and dissolved in 1 mL of lysis buﬀer (PBS 50 mM, NaCl 0,5M,
NP40 1%, DOC 0,5%, SDS 1%) containing a protease inhibitor
cocktail (Protease Inhibitor Cocktail 100x, Thermo Fisher
Scientiﬁc, Waltham, MA, USA) and not oxidized glutathione to
preserve the disulﬁde bond of the Sulfo-NHS-SS biotin reagent.
Subsequently, the samples were sonicated (2 × 30 s) using a 2
mm microprobe (Vibra-Cell 75022, Bioblock Scientiﬁc, Illkirch,
France; Sonication parameters: sample temperature = 4 °C,
amplitude = 30 and pulser = 2 s). Finally, protein concentration
was determined using the BCA protein assay reagent kit
(Pierce, Thermo Fisher Scientiﬁc, Waltham, MA, USA). In
order to isolate the biotinylated proteins, the necessary amount
of streptavidin−sepharose resin (Amersham Biosciences, 150
μL/mg of total protein extract) was equilibrated by ﬁve washes
in buﬀer A (1% NP40 and 0.1% SDS in PBS 50 mM).
Following this, the total protein lysate and streptavidin resin
were mixed together and incubated for 2 h at RT under
constant rotation. After the incubation, the unspeciﬁc binding
was reduced by washing the resin four times with buﬀer A, four
times with buﬀer B (0.1% NP40, 1 M NaCl in PBS), twice with
buﬀer C (0.1 M sodium carbonate in PBS, pH 11), and once
with a solution of NaCl (0.5 M) in PBS (50 mM). The
biotinylated proteins were eluted using 100 mM DTT solution
(2 × 30 min at 60 °C), alkylated with 150 mM iodoacetamide
(30 min at RT in the dark) and ﬁnally precipitated with 20%
trichloroacetic acid (overnight at 4 °C). The protein pellet was
washed twice with pure prechilled (−20 °C) acetone and
allowed to dry for 5 min at RT. Finally the pellet was dissolved
in 50 μL of 200 mM ammonium bicarbonate buﬀer, and the pH
was adjusted to 8.0 (with 100 mM HCl). Protein concentration
was determined using the BCA protein assay. For the mass
spectrometry investigation, the dissolved proteins were digested
with trypsin (Promega, Madison, WI, USA; porcine, sequencing
grade, catalogue no. V551A; 1/50, protease/protein) overnight
at 37 °C followed by second digestion using fresh trypsin (1/
100) for additional 4 h. Prior to injection in the nanoHPLC
system, a quantity corresponding to 5 μg of peptides was
desalted using ZipTip (Millipore, Billerca, MA, USA) according
to the manufacturer’s instructions. Subsequently, the peptides
were lyophilized and dissolved in 20 μL water containing 0.1%
formic acid.
Mass Spectrometry Analysis
The peptide-containing samples were analyzed on the 2D-
nano-HPLC system Ultimate 3000 (Dionex, Sunnyvale, CA,
USA) connected online to the electrospray ion-trap mass
spectrometer Esquire HCT ultra (Bruker Daltonics, Bremen,
Germany) as described previously.22 The acquired spectra were
processed for peak-list generation using the Data Analysis
software version 3.4 (Bruker Daltonics, Bremen, Germany).
The peak-list ﬁles from all fractions were combined into one ﬁle
for each individual animal and disease state. These combined
ﬁles were submitted to the Swissprot database using the Mascot
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SRC8 Q60598 5 41 3 6 4 101 3 7 2.1 ± 0.5 Cy; PM
SPRL1 P70663 4 46 3 7 2 61 4 9 2.5 ± 0.1 S
SC6A1 P31648 1 62 1 4 3 57 2 4 PM; M
APOE P08226 1 65 3 15 3 59 2 8 S
SAP Q61207 1 154 6 13 3 62 2 5 E
MRP P28667 n.d. 3 68 2 11 PM
PICA Q7M6Y3 n.d. 3 108 3 5 M
TKT P40142 n.d. 2 74 2 7 U
ITB1 P09055 n.d. 1 87 6 9 PM
human
POTEE Q6S8J3 n.d. 6 358 8 11 U
CAC1S Q13698 n.d. 6 71 4 2 M
OPCM Q14982 n.d. 5 156 2 11 PM
GDS1 P52306 n.d. 5 104 3 5 U
PTPRZ P23471 n.d. 4 174 3 2 M
PCDH1 Q08174 n.d. 4 68 2 3 PM
BOD1L Q8NFC6 n.d. 4 50 4 2 U
S19A1 P41440 n.d. 3 36 2 2 M
DCD P81605 n.d. 2 76 2 16 S
HBD P02042 n.d. 2 73 3 22 E
FIBB P02675 n.d. 2 50 2 7 S




6 122 4 6 6/6 159/
791





1 41 3 7 3/3 153/
102
3/4 8/10 PM; Cy
FXYD6 Q9H0Q3/
Q9D164
n.d. 3/2 74/51 1/1 23/23 M
U373
mouse
SPRL1 P70663 4 46 3 7 2 72 4 8 2.0 ± 0.0 S
UBQL2 Q9QZM0 1 89 1 3 3 76 2 3 M; N; Cy
CLD11 Q60771 1 83 1 7 3 89 1 7 PM
PPM1H Q3UYC0 1 44 2 5 3 49 2 4 U
MAGI1 Q6RHR9 n.d. 2 54 4 3 PM; Cy
ITB1 P09055 n.d. 1 48 3 4 PM
human
GDS1 P52306 n.d. 6 89 3 7 U
POTEE Q6S8J3 n.d. 5 485 6 9 U
CAC1S Q13698 n.d. 5 68 4 2 M
OPCM Q14982 n.d. 5 60 1 4 PM
PCDH1 Q08174 n.d. 5 65 4 5 PM
BOD1L Q8NFC6 n.d. 5 42 4 2 U
PTPRZ P23471 n.d. 3 74 2 1 M
HBB P68871 n.d. 3 122 3 24 E
RCCD1 A6NED2 n.d. 3 48 1 3 U
POTEI P0CG38 n.d. 3 112 4 5 U
GNAI1 P63096 n.d. 2 62 2 7 PM; N; Cy
AT2B3 Q16720 n.d. 2 168 4 4 PM
AT2B1 P20020 n.d. 2 200 5 5 PM
DLG2 Q15700 n.d. 2 55 5 8 M; PM
S4A4 Q9Y6R1 n.d. 2 44 3 3 PM




6 122 4 6 3/6 123/
416
3/9 5/19 0.73 ± 0.1/4.8
± 1.5
PM
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search engine version 2.2.2 (Matrix Sciences, Boston, MA,
USA). A homemade database (for details see below), consisting
of the most recent (April, 2012) human and mouse protein
entries was used (human number of entries = 20,225; mouse
number of entries = 16,539; both obtained from Swissprot).
The mass tolerances of precursor and fragmented ions were set
at 0.6 and 0.3 Da, respectively; ﬁxed modiﬁcations were
carbamidomethyl; variable modiﬁcation was oxidization of
methionine; peptide charges were set at +2 and +3. Trypsin
cuts before proline and one missed cleavage were allowed. As
far as the Mascot report parameters are concerned, the
following formatting was used: signiﬁcance threshold = p <
0.05, ions score cutoﬀ = 30, show subsets = 1, require bold red
= unchecked. The false discovery rate (FDR) was calculated
utilizing the “on ﬂight” decoy function of the Mascot search
engine.
Semi-quantitative analysis was performed for the proteins
that were identiﬁed in both tumoral and normal samples and in
more than two animals. The Mascot results yielded protein
identiﬁcations along with the exponentially modiﬁed protein
abundance index (emPAI). Ishihama et al.23 showed that the
emPAI value is directly proportional to the protein quantity
(for details see Supporting Information). Relative expression
ratios were calculated from individual emPAI values (tumor/
normal). Mice homologue proteins found in the normal brain
served as the reference when expression ratios were calculated
for human proteins. This speciﬁc case occurred particularly
when no discrimination of protein origin was possible
(“common” proteins in the Table 1), and hence the pool of
peptides used for the quantiﬁcation of protein expression
(between the two homologue proteins) had identical
sequences. The normalization of protein expression ratios was
conducted assuming a Gaussian distribution of the data (where
the maximum number of the proteins has an relative expression
ratio of 1.0). Proteins that were not eligible for emPAI
quantiﬁcation (not present in at least two animals) were
screened for the frequency of presence or absence in all the
samples. The proteins that were identiﬁed more frequently in
the tumoral condition in comparison to the normal counterpart
were also considered as potentially modulated.
Determination of Protein Origin
In the present experimental setup where human cells were
xenografted in murine brain, a set of analysis was performed in
order to discern the origin of all modulated proteins.
Accordingly, all data sets were searched against a homemade
database (DB), which consisted of both murine and human
protein sequences. In this manner it was possible to distinguish
three protein groups: (i) identiﬁed uniquely as mouse and (ii)
identiﬁed as human, and those which (iii) were reported as
both human and mouse. The latter group was the point of
major interest, as it was important to determine if some of
those proteins had peptides that were unique to the mouse or
to human species. The analysis therefore consisted of
examining the sequence coverage with respect to the mouse
or human canonical protein sequence. Those proteins that
displayed (i) more sequence coverage for the mouse sequence
and had also (ii) unique peptides found only in mouse DB were
considered as host produced (mouse) proteins. Conversely,
proteins that displayed more sequence coverage for the human
sequence and displayed unique peptides in human DB were
attributed to human tumor cells. Diﬀerences in the amino acid
sequence were conﬁrmed by examining the MS/MS spectra. A
peptide was considered unique for a given species if it
contained a part of the sequence from non-homologous
protein region. Modiﬁcations in single amino acids were not
considered to be of a “unique character” as single nucleotide
polymorphism might have contributed to such sequence
variations.
Validation of Protein Expression Using WB
In order to validate the MS data indicating an overexpression of
a particular protein, targeted WB analysis was employed. For
this purpose brains of 3 normal, 3 U373, and 3 T98G animals






























n.d. 2/2 71/71 2/2 5/5 PM; Cy
RB43L A6NDJ8 n.d. 2/2 77/77 2/2 15/15 U
F123A Q8N7J2/
Q8CCJ4
n.d. 2/1 42/45 2/3 4/5 U
HXK3 P52790/
Q3TRM8
n.d. 1/2 70/63 3/3 6/4 E; Cy
MRP P49006/
P28667
n.d. 1/1 67/67 2/2 13/13 PM
aThe data are divided into three main groups: proteins conﬁrmed as of (i) human origin and (ii) mouse origin and (iii) present both in human and
mouse. In cases where the protein was identiﬁed both in normal and tumoral tissue, semi-quantitative protein quantiﬁcation was conducted using the
emPAI method (detailed in Material and Methods section). In the absence of emPAI (protein not found in the normal tissue), the number of
biological replicates in which the respective protein was observed served as a semi-quantitative indicator of protein abundance (n.d. stands for not
detected). Each individual protein hit was further characterized with the score (Mascot), the number of unique peptides found in the MS analysis,
and the sequence coverage. When these parameters are reported for both species in the same column, the number in italics and underlined indicates
the value for the human species. Uniprot database and Gene Ontology was used to infer the potential sub-cellular localization for each of the
identiﬁed proteins. Following abbreviations are used: S, secreted; E, extracellular; PM, plasma membrane; Cy, cytoplasm; N, nucleus; M, membrane;
and U, unknown. The quantiﬁcation error is expressed as standard deviation of means (SD). Accession numbers refer to the Swiss-Prot database.
Full protein names are outlined in the Supplemental Table S1.
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SDS water solution containing protease inhibitors. Twenty
micrograms of protein extracts were then heated for 5 min and
separated by SDS-PAGE gel electrophoresis. Subsequently, the
separated proteins were transferred onto PVDF membrane
(Roche, Mannheim, Germany) at 30 V (4 °C) overnight. The
membranes were blocked for 2 h at RT in TBS-T (150 mM
NaCl, 100 mM Tris, 0.1% Tween-20, pH 7.5) containing 5%
nonfat dried milk (Biorad, Hercules, CA, USA). Subsequently,
the membranes were incubated with diluted primary antibodies
(anti-SPRL1, 1:500, cat. no. AF2728, R&D systems, Minneap-
olis, MN, USA; anti-SAP, 1:1000, cat. no. 10801-1-AP,
Proteintech, Manchester, U.K.; anti-ITB1, 1:500, cat. no.
ab52971, Abcam, Cambridge, U.K.; anti-MRP, 1:500, cat. no.
11422-1-AP, Proteintech) for 2 h at RT. Following three TBS-
T 10 min washes, the membranes were incubated for 1 h at RT
with speciﬁc secondary antibody conjugated to horse radish
peroxidase. The membranes were rinsed three times with TBS-
T followed by two washes with TBS. Finally, the immunoblots
were visualized using ECL Western blotting substrate (Pierce).
α-Tubulin (TUBA) was used for normalization.
Immunohistochemical Analysis of SPRL1 Protein
The protein expression of SPRL1 was further studied using
immunohistochemistry; the polyclonal anti-SPRL1 antibody
was used at the dilution 1/50 (type and vendor as indicated
above). The protein expression analysis was conducted on the
tumor bearing mouse brain tissues (both U373 and T98G),
human glioma (all grades), and normal brain tissues. In total, 4
animals per tumoral/normal condition as well as 23
glioblastoma, 8 astrocytoma grade III, 8 astrocytoma grade II,
7 astrocytoma grade I, and 5 normal adjacent tissues were
evaluated.
The tissues were sliced from paraﬃn blocks (5 μm sections),
deparaﬃned 2 times in xylene for 5 min, and hydrated in the
methanol gradient (100%, 95%, 70%, and 50%). Blocking of
unspeciﬁc peroxidase was performed for 30 min with 3% H2O2
and 90% methanol. The incubation with the primary antibody
was performed overnight at 4 °C. The biotinylated secondary
antibody was incubated initially for 30 min and subsequently
with the avidin−biotin complex kit (ABC kit) for an additional
30 min. 3,3′-Diaminobenzidine tetrachlorhydrate dihydrate
(DAB) with 5% H2O2 was used for staining. The slides were
counter-stained with hematoxylin.
Two neuropathology experts examined the tissue positivity
independently. Evaluation of the antigen positivity was
conducted for the intensity and the extent of the staining.
The intensity value 0 denoted an undetectable staining, whereas
1, 2, or 3 denoted low, moderate, and strong immunoreactivity,
respectively. Regarding the staining extent, values of 1, 2, 3, or 4
denoted samples in which ≤25%, 26−50%, 51−75%, or 76−
100% of the tissue showed immunoreactivity, correspondingly.
The results obtained by these two scales were then multiplied
together to yield a single value, named score. Following this, a
ratio of tumoral versus normal brain was calculated. Statistical
analyses and graphs were performed using Excel software
(Microsoft, Redmond, WA, USA). Statistical signiﬁcance of the
antigen modulation was assessed using a two-tailed Student’s t
test.
■ RESULTS
Accessible Proteins Are Diﬀerentially Modulated in
Glioblastoma in Vivo
Using two diﬀerent high grade in vivo glioma models (T98G
and U373), the current proteomic study highlighted a distinct
group of up-regulated and accessible proteins. The workﬂow of
the study including the method used is outlined in Figure 1.
Overall, 1081 and 1024 proteins were identiﬁed from the
analysis of the T98G and U373 derived tumors, respectively
(Figure 2). The mean FDR of the analysis (considering all
samples) was 3.34% considering peptide matches above the
identity threshold. Among the identiﬁed proteins three diﬀerent
groups were discernible: (i) human (27% [T98G] and 11%
[U373]), (ii) mouse (44% and 51%), and (iii) a common set of
proteins (29% and 38%) that could not be unambiguously
assigned to either category (Figure 2A). Of all the proteins
identiﬁed (in both models), one-tenth was up-regulated in the
glioblastoma in comparison to the normal brain (Figure 2B).
One-quarter of the up-regulated proteins were of membrane
and extracellular origin (Figure 2C), and this group is displayed
in Table 1. In the current study, a protein was considered as up-
regulated when the ratio of protein abundance (emPAI)
between the tumoral and normal specimen exceeded the 2-fold
modulation or the protein was identiﬁed at least two times
more often in the tumoral than in the normal condition.
Proteins identiﬁed in only one tumoral condition were also
Figure 2. Overview of the identiﬁed proteins in two tumor models at
diﬀerent steps of analysis. The charts on the top (A) indicate the
numbers of mouse, human, and undetermined proteins following the
database search of MS/MS data. Below, chart B displays the number of
up-regulated proteins following the comparison of each tumoral
sample with the normal brain. Finally, chart C shows the percentage of
up-regulated proteins that are potentially of accessible nature (Uniprot
database).
Journal of Proteome Research Article
dx.doi.org/10.1021/pr3005698 | J. Proteome Res. 2012, 11, 5011−50215016
included if they had at least 2 unique peptides. The subcellular
localization of a given protein was determined on the basis of
Gene Ontology or available literature information. Because of
the speciﬁcity of the sample preparation method, proteins with
currently unknown localization were included as well. These
proteins are likely to be of extracellular and membrane origin
and are hence treated as potentially accessible (Table 1).
SPRL1, SAP, ITB1, and MRP Are Conﬁrmed as
Overexpressed Proteins in Human Glioblastoma Model
Because little is known regarding their possible implication in
high-grade gliomas, several proteins from Table 1 have
attracted particular attention. Therefore, SPRL1, SAP, ITB1,
and MRP were selected and further validated using WB analysis
(Figure 3). This step was particularly important as some of the
selected proteins (ITB1 and MRP) were identiﬁed only once in
the MS analysis. As indicated in Figure 3, all proteins proved to
be expressed in either of the glioma models, and except for
MRP none was detected in the normal mouse brain. MRP was
detected in one out of three normal brains. ITB1 and SAP were
not detected in normal mice brain; however, they were found
to be present in only one out of three T98G xenografts and
absent in the U373 model (some faint bands of ITB1 in U373
were detected too). Notably only SPRL1 was validated as
overexpressed in all three T98G and one U373 xenografts.
However, MS analysis has identiﬁed SPRL1 in the normal mice
brain too, and therefore it is to be assumed that this protein is
expressed in the mice brain but at much lower concentration
than in glioma.
Glial Cells Overexpress SPRL1 in a Mouse Model of Human
Glioblastoma
In order to further investigate the expression of SPRL1 in the
present glioblastoma mouse model, corresponding immunohis-
tochemistry analysis was performed on paraﬃn ﬁxed tissues
(Figure 4C−E). The data indicated, in agreement with Western
blot analysis, a strong overexpression of SPRL1 in both T98G
and U373 mice gliomas. Staining in both tumor types displayed
distinct cytoplasmatic positivity with some diﬀuse expression
localized in the extracellular milieu. In normal mouse brain
SPRL1 staining exhibited strong nuclear positivity in some
neuronal cells; however, most of the cells were negative. In
addition, IHC data suggests that SPRL1 is present in both
normal and tumoral brains (in line with MS analysis); however,
the types of cells expressing this protein (glial in the tumor and
neuronal in the normal brain) as well as the amounts produced
appear to be diﬀerent.
SPRL1 Is Overexpressed in Human Glioma and Positively
Correlates with the Tumor Grade
Following the conﬁrmation of SPRL1 overexpression in the
mouse model, additional IHC studies were directed towards
evaluating the expression of this protein in human glioma
samples. As shown in Figure 5A, a general increase of staining
intensity is observed with evolving astrocytoma grade. In more
detail, glial cells displayed medium to strong SPRL1
cytoplasmatic immunoreactivity (granular pattern) in glioblas-
tomas and type III astrocytomas. The staining was of moderate
to weak intensity in grade I and II astrocytomas and weak to
negative in normal human brain. As far as the extensivenes of
the staining is concerned, it can be stated that less than 25% of
positive cells were detected in normal tissue and grade I and II
astrocytomas, whereas more than 75% of cells were found to be
reactive in grade III astrocytomas and glioblastomas. Occasion-
ally, in glioblastomas, SPRL1 displayed moderate cytoplasmic
immunoreactivity (diﬀuse pattern) in parallel to cytoplasmic
expression in neoplastic blood vessels and normal endothelial
cells (diﬀuse pattern) (Figure 5B). In normal positive tissue,
SPRL1 also exhibited immunoreactivity in scattered endothelial
cells (moderate cytoplasmic, diﬀuse pattern) and in few
neuronal cells (strong cytoplasmic, granular pattern) (Figure
5B), similar to the observations made in mice glioma model.
Overall expression analysis conﬁrmed the overexpression of
SPRL1 in human gliomas, with statistical values supporting a
signiﬁcant correlation to increasing disease progression (Figure
5C). Given the rather limited number of cases investigated in
the current study, grade 4 (glioblastoma) was clearly
distinguished from other glioma grades (p ≤ 0.05). This
statistical strength can at least in part be attributed to a larger
number of grade 4 cases involved in the current study (N = 23).
Furthermore the IHC analysis could clearly highlight grade 3
gliomas as diﬀerent from grade 1 and 4. Statistical signiﬁcance
however decreased when grade 1 and 2 as well as 2 and 3 were
compared. In this case, the number of cases being analyzed
could be considered as one of the limiting factors (N = 8 [for
grade 2 and 3] and N = 7 [for grade 1]) to demonstrate the
statistical signiﬁcance of SPRL1 expression and to distinguish
between diﬀerent degrees of disease progression.
■ DISCUSSION
The speciﬁc experimental setup, where human cancer cells are
xenografted in mouse model (here brain), was employed in the
past with other tumor models24−30 and oﬀered in the current
study the potential to distinguish the modulated proteins by
their origin (host versus tumor). Mass-spectrometry-based
high-throughput peptide sequencing enabled to a certain
degree sorting between human and mouse protein fragments.
In some cases of proteins that are highly conserved between the
two species, the protein origin could not be clearly
distinguished. Apart from these obvious limitations, character-
izing host response for gliomas is particularly diﬃcult since
Figure 3. Western blot analysis of SPRL1, ITB1, MRP, and SAP
protein expression in normal, T98G, and U373 xenografted mice
brain. Three individual samples (animals) were used per condition.
Normalization was conducted with α-tubulin.
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these tumors arise from glial cells, which under normal
circumstances constitute the brain's supportive matrix.
However, proteins arising from the host reaction are likely to
be more stable than the one produced by the genetically
evolving glioma cells and hence could be more suitable as
eﬃcient targets for therapy applications. Therefore in gliomas it
is challenging to tell apart proteins that originate from (or are
diﬀerentially expressed in) “normal” versus tumoral glial cells.
However, the strategy applied in the current study proved to be
an appropriate tool for providing information on host vs
tumoral response.
Proteins that are of interest for targeted therapies or imaging
technologies require to be deposited/immobilized in the tumor
tissue and should not be systemically distributed. We therefore
chose to speciﬁcally focus on exactly this group proteins,
employing a previously published ex vivo tissue biotinylation
approach.19,20 Overall, in the current study over 1000 proteins
were identiﬁed and quantiﬁed in both cell lines, of which two-
thirds were assigned to either human or mouse species. Of the
identiﬁed proteins, ∼one-half was assigned to mouse and ∼one-
quarter to human origin depicting the skewed ratio of normal
(mouse) to tumoral (human) cells. In order words, the tumoral
mass is clearly underrepresented in the xenografted brains, and
this is also conﬁrmed in corresponding histological analysis
(Figure 4A and B). Certainly, bringing this ratio to a more
equal level would improve the analysis, providing equal
analytical coverage to both tumor and host tissue. One possible
way could be the microdissection of the tissue; however,
current proteomic methods are challenged with handling such
minute protein amounts. Interestingly, as the analysis moved
toward extracting only targets with up-regulated expression,
considerably more human (∼one-half) then mouse (∼one-
quarter) proteins were highlighted. This ﬁnding could possibly
indicate that the reactive host tissue is “diluted” in the “non-
reactive” remaining normal brain. In this way, a signiﬁcant part
of modulated host proteins could remain unidentiﬁable. Aiming
to uncover this concealed group of proteins could help further
characterize the host response in cancer.
Following mass spectrometry analysis, including subsequent
IHC and Western blot validation steps, SPRL1 (also known as
hevin) appeared particularly interesting for further studies in
human glioma samples. This protein has been found previously
to be expressed in the extracellular matrix of many normal
human tissues.31 We conducted an additional in silico survey
based on the Gene Cards database (http://www.genecards.
org), which conﬁrmed this observation. This database compiles
information on mRNA expression in a total of 23 diﬀerent
normal human tissues hybridized against the Aﬀymetrix HG-
U95A-E and HG-U133A DNA-microarrays, respectively.32 The
results are presented in the Supporting Information (Figure
S1), indicating that SPRL1 has probably an important
physiological role. To this end, literature shows that SPRL1 is
Figure 4. (A−E) Histological evaluation of T98G and U373 tumors. Hematoxylin & eosin staining of T98G and U373 mouse brain xenografts (A,
B). Magniﬁcation 200X. Both images include a magniﬁed (400X) portion of the tumor (top left corner). Immunohistochemical analysis of SPRL1
protein expression in normal mouse and xenografted brain (C−E). Strong positivity was detectable in both T98G (C) and U373 (D) mouse brain
xenografts. SPRL1 expression was generally negative in normal mouse brain, apart from distinct positivity that was observable in some glial cells (E).
Magniﬁcation 400X. All images are representative of 3 independent histological evaluations.
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expressed on the basal, lateral, and apical surfaces of endothelial
cells but not at the basement membrane.33 From a functional
point of view SPRL1 inhibits attachment and spreading of
endothelial cells to ﬁbronectin (in vitro), preventing these from
forming focal adhesions.33 SPRL1 is also known to bind
collagen-I34 and can regulate decorin production and collagen
assembly.35
In cancer, the role of SPRL1 remains poorly understood. Of
the studies examining the expression of SPRL1 in tumor, down-
regulation of this protein was reported in metastatic prostate
adenocarcinoma,36 non-small cell lung cancer,37 and gastric
cancer.38 Notably, in the study of Li and colleagues, SPRL1
positive patients exhibited a better median survival than SPRL1-
negative patients. Up-regulation of SPRL1 was observed in
Figure 5. (A−C) Immunohistochemical analysis of sparc like-1 (SPRL1) protein expression including statistical evaluation. Panel A shows SPRL1
expression in normal brain, followed by astrocytoma grade I to III and glioblastoma (astrocytoma grade IV). Distinct staining patterns in the
neoplastic and normal vessels of the glioblastoma samples as well as SPRL1 staining in the neurons of the normal tissue are shown in panel B. Images
are displayed at 400x magniﬁcation and are representative of respective biological replicates (as indicated in Materials and Methods). Statistical
evaluation of relative protein expression (normalized to normal human brain) indicates a partially signiﬁcant trend (not signiﬁcant [at p ≤ 0.05]
between grades 1 and 2 as well as 2 and 3; signiﬁcant [at p ≤ 0.05] between grades 1 and 4; 1 and 3, 4, and 2; as well as 3 and 4) of increasing SPRL1
expression with the glioma grade (C).
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pancreatic cancer,39 colorectal adenocarcinomas,40 and hep-
atocellular cancer.41 Due to this apparent evidence of both up-
and down-regulation of this protein in cancer, SPRL1 will
probably assume diﬀerent roles in diﬀerent types of
malignancies. In the context of glioma, the study of Lau et al.
is particularly interesting as the authors observed that SPRL1
expression correlates with tumor angiogenesis.41 One of the
most important features of glioblastoma, in comparison to the
lower grade gliomas, is the appearance of prominent angio-
genesis. New vessels supply critical nutrients required for the
aggressive growth of these glial tumors. The current study ﬁts
another piece of the puzzle as it demonstrates that increasing
SPRL1 expression accompanies glioma progression from low to
high grades. Therefore, one of the key hypotheses to test in
future work would concern the putative pro-angiogenic
function of SPRL1 in human glioblastoma. Finally, another
aspect of SPRL1 that may prove interesting concerns the
protein's striking homology with SPARC (over 50% of amino
acid sequence is shared). SPARC (also referred to as
osteonectin) is known to be anti-adhesive and is implicated
in cancer in G1 to S phase cell cycle progression, regulation of
extracellular matrix via metalloproteinases, and interaction with
platelet-derived and vascular endothelial growth factors.42
Previously our group has reported high SPARC levels in breast
cancer.43 Taken together, it is not unreasonable to assume that
the function of sparc-like protein 1 is important in the
physiological and pathophysiological process in a similar
fashion to the homologue SPARC. This further hypothesis
merits additional studies regarding the precise function of
SPRL1 in human cancer.
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